ConclusionPremature discontinuation of initial AI therapy as a result of symptoms is common, although more than one third of patients may be able to tolerate a different AI medication. Additional research is needed to identify predictive tools and interventions for AI-associated treatment-emergent symptoms. (Source: Journal of Clinical Oncology) read more..
F Cancer: Meet The 25-Year-Old Entrepreneur Who's Raised Over $1M For Early Detection, Prevention
Several years ago, Yael Cohen got the news that nobody wants to hear. Her mother had been diagnosed with breast cancer. Rushing to be by her side, she sat through doctor?s appointments, meetings with surgeons, and treatment. Through it all, she saw firsthand what an emotional roller-coaster the disease can be. (Source: Forbes.com Healthcare News) read more..